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Università degli Studi di Bologna, via Irnerio 48, Bologna 40126, Italy
b ITOI-CNR, Sezione di Bologna, c/o IOR, Bologna, ItalyReceived 20 February 2004; accepted 17 March 2004
Available online 28 May 2004Abstract
Previous evidence from independent laboratories has shown that the nucleus contains diacylglycerol kinase (DGK) isoforms, i.e., the
enzymes, which yield phosphatidic acid from diacylglycerol, thus terminating protein kinase C-mediated signaling events. A DGK isoform,
which resides in the nucleus of PC12 cells, is DGK-u. Here, we show that nerve growth factor (NGF) treatment of serum-starved PC12 cells
results in the stimulation of both a cytoplasmic and a nuclear DGK activity. However, time course analysis shows that cytoplasmic DGK
activity peaked earlier than its nuclear counterpart. While nuclear DGK activity was dramatically down-regulated by a monoclonal antibody
known for selectively inhibiting DGK-u, cytoplasmic DGK activity was not. Moreover, nuclear DGK activity was stimulated by
phosphatidylserine, an anionic phospholipid that had no effect on cytoplasmic DGK activity. Upon NGF stimulation, the amount and the
activity of DGK-u, which was bound to the insoluble nuclear matrix fraction, substantially increased. Epidermal growth factor up-regulated a
nuclear DGK activity insensitive to anti-DGK-u monoclonal antibody. Overall, our findings identify nuclear DGK-u as a down-stream target
of NGF signaling in PC12 cells.
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Over the last 15 years, several investigations have
focused on the study of nuclear lipid-metabolizing enzymes
[1–3]. Nuclear lipid metabolism is stimulated by various
types of agonists and, remarkably, is operationally separated0898-6568/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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many agonists that stimulate the membrane cycle do not
activate the nuclear cycle and vice versa. In other cases, if
an agonist stimulates both cycles, it does so in a temporally
distinct manner [4].
The activation of lipid metabolism within the nucleus
leads to the generation of second messengers such as
diacylglycerol (DG), which can derive from either inositol
lipids or phosphatidylcholine (PC) [5]. The role played by
DG in attracting to the nucleus some DG-dependent protein
kinase C (PKC) isoforms (conventional PKC-a, -hI, -hII, -g,
and novel PKC -y, -q, -D, -u) is now widely accepted [1,6],
however, this lipid second messenger also modulates other
signaling proteins, such as the guanine nucleotide exchanger
factor vav, whose presence within the nucleus has been
reported [7,8].
One of the major routes for terminating DG signaling is
by its phosphorylation to phosphatidic acid (PA) by diac-
ylglycerol kinase (DGK), which, in mammals, comprises a
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further organized into five subfamilies: class I comprises
the a, h, and g isozymes; class II the y and D; class III the q
isoform; class IV the ~ and L; class V the u [9,10]. All of the
mammalian DGKs share a conserved catalytic domain in the
COOH-terminal region and at least a pair of cysteine-rich
motifs (DGK-u has three) similar to the C1A and C1B
motifs of PKC, but lacking certain consensus residues
present in phorbol ester-binding proteins. DGK isotypes
can be distinguished by the presence of additional domains
that conceivably confer to each isozyme specific functions
in biological processes, sensitivity to different regulatory
mechanisms, and a differential intracellular localization
[9,10].
Interestingly, PA also has signaling functions, as it can
modulate the activity of several enzymes including PKC-~ ,
Ras-GTPase activating protein, and phosphatidylinositol-4-
phosphate 5-kinase (PI(4)P 5-kinase) [11–13]. Moreover,
PA has a role in actin polymerization [14]. Since they can
attenuate local accumulation of signaling DG, DGKs play a
pivotal role in many biological responses including cell
proliferation, differentiation, survival, and apoptosis [9,10].
Several DGK isoforms (-a, -g, -y, -~ , -u) localize to the
nucleus (reviewed in Ref. [15]). It has been demonstrated
that DGK-~ plays a key role in the control of intranuclear
DG levels and, as a consequence, it regulates cell prolifer-
ation [16]. Regarding nuclear DGK-u, it is activated in
response to a-thrombin stimulation of IIC9 fibroblasts, an
experimental model in which there is an increase in nuclear
PC-derived DG mass due to an up-regulation of nuclear
phospholipase D (PLD) [17]. We recently reported that in
PC12 cells, nuclear DGK-u is concentrated in distinct
subnuclear domains, referred to as nuclear speckles [18].
Interestingly, components of the nuclear inositide metabo-
lism, including phosphatidylinositol-4,5-bisphosphate
(PI(4,5)P2) and PI(4)P 5-kinase, are localized within the
speckles [19,20].
Previous results have indicated that in response to nerve
growth factor (NGF) treatment of PC12 cells, there is an
increase in the amount of nuclear DG [21]. Thus, it could be
hypothesized that a nuclear DGK isozyme is activated in
response to NGF treatment of PC12 cells, as it happens in
the case of insulin-like growth factor-1 (IGF-1)-treated
Swiss 3T3 cells, i.e., another experimental system in which
a rise in nuclear DG has been reported [22–24]. With the
above in mind, we decided to investigate whether or not
NGF up-regulates nuclear DGK-u activity of PC12 cells.
We have found that nuclear DGK activity increases in
response to NGF exposure. This activity was inhibited by
a monoclonal antibody, which has been previously shown to
be capable of selectively down-regulating DGK-u [17]. In
contrast, epidermal growth factor (EGF), which has a
proliferative effect on PC12 cells, activated a nuclear
DGK activity insensitive to the anti-DGK-u antibody. Taken
together, our results identify nuclear DGK-u as a specific
down-stream target of NGF-elicited signaling pathways.2. Materials and methods
2.1. Source of materials
Tissue culture media components, protease and phospha-
tase inhibitors, dithiothreitol, detergents, normal goat serum
(NGS), bovine serum albumin (BSA), octylglucoside (OG),
phosphatidylserine (PS), DG (dioleoyl), L-a-PA (dioleoyl),
anti-h-tubulin monoclonal antibody, Cy3-conjugated anti-
mouse IgG, and peroxidase conjugated anti-mouse IgG were
from Sigma Chemical company, (St. Louis, MO).) DGK
inhibitor R59949 was obtained from Calbiochem, (La Jolla,
CA). Anti-DGK-u monoclonal antibody (IgG1) was from
BD Transduction Laboratories, (Milan, Italy). Anti-lamin B
monoclonal antibody was from Chemicon International,
(Temecula, California). Mouse IgG1 was purchased from
DakoCytomation, (Glostrup, Denmark). NGF was from
Upstate Biotechnology Incorporated, (Lake Placid, NY).
Mouse EGF, the Lumi-LightPlus enhanced chemilumines-
cence (ECL) detection kit, and RNase-free DNase I were
from Roche Applied Science, (Milan, Italy). [g-32P] ATP
was from Amersham Biosciences, (Milan, Italy). Silica Gel
G-60 thin layer chromatography (TLC) plates was from
Whatman (Maidstone, United Kingdom). The Protein Assay
kit (detergent compatible) was from Bio-Rad, (Hercules,
CA).
2.2. Cell culture
Rat pheocromocytoma PC12 cells were cultured in
Dulbecco’s modified minimum essential medium (D-
MEM) containing 10% heat-inactivated horse serum and
5% heat-inactivated fetal calf serum. Prior to stimulation
with 100 ng/ml NGF for the indicated times, 50% confluent
cells were switched to serum-free medium (D-MEM plus
0.5% BSA) overnight. EGF was used at 40 ng/ml.
2.3. Preparation of cytoplasmic fraction
Cells were resuspended in 10 mM Tris–Cl, pH 7.4, 10
mM NaCl, 2 mM MgCl2, 1.0 mM phenylmethylsulphonyl
fluoride (PMSF), 10 Ag/ml soybean trypsin inhibitor, 1 Ag/
ml of leupeptin and aprotinin, 1.0 mM Na3VO4, 20 nM
okadaic acid. They were incubated at room temperature for
2 min, cooled in ice water for 5 min, and homogenized on
ice in a Dounce homogenizer with a type A pestle. Crude
nuclear fraction was removed from the total homogenate by
centrifugation at 400 g for 15 min. The supernatant was
used as cytoplasmic fraction.
2.4. Isolation of nuclei
This was accomplished as previously reported, with
minor changes [21]. Briefly, cells were resuspended in 10
mM Tris–Cl, pH 7.4, 10 mM NaCl, 2 mM MgCl2, 1.0 mM
PMSF, 10 Ag/ml soybean trypsin inhibitor, 1 Ag/ml of
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acid. They were incubated at room temperature for 2 min,
cooled in ice water for 5 min, then Nonidet P-40 was added
to a final concentration of 1%. After a passage through a 22-
gauge needle, the concentration of MgCl2 was adjusted to 5
mM. The samples were centrifuged at 600 g for 5 min.
and washed once in 10 mM Tris-–Cl, pH 7.4, 5 mM MgCl2,
plus protease and phosphatase inhibitors as above. The
purity of nuclear preparations was evaluated by Western
blot analysis using a monoclonal antibody to h-tubulin. The
absence of immunoreactivity to the cytoskeletal protein in
isolated nuclear preparations confirmed that the isolation
procedure yielded nuclei of high purity that were free of
cytoplasmic contaminants.
2.5. Preparation of nuclear matrix
Nuclear matrices were isolated according to Belgrader et
al. [25], with modifications. Briefly, isolated nuclei from
PC12 cells were digested with 40 IU/mg DNA of RNase-
free DNase I for 30 min at 4 jC. Subsequently, the
chromatin-associated proteins were released by adding
dropwise 2 M (NH4)2SO4 to a final concentration of 0.6
M (NH4)2SO4. After 15 min of incubation on ice, the
nuclear matrices were pelleted at 1,500 g for 15 min
and washed once in 10 mM Tris–HCl, pH 7.4, 0.2 mM
MgCl2.
2.6. Protein assay
This was performed according to the instruction of
the manufacturer using the Bio-Rad Protein Assay
(detergent-compatible).
2.7. DGK in vitro activity assay
This was accomplished essentially as reported elsewhere
[17,24], using OG/DG mixed micelles. OG/DG mixed
micelles were prepared as follows: a mixture of 0.25 mM
DG, 55 mM OG, and PS (either 1 mM resulting in 1.8% in
micelles or 5 mM resulting in 8.3 mol% in micelles) was
resuspended in 1 mM diethylenetriamine pentaacetic acid,
pH 7.4, by vortexing and sonicating until the suspension
appeared clear. Twenty microliters of mixed micelles were
added to 70 Al of the reaction mixture (final concentration:
100 AM diethylenetriamine pentaacetic acid, pH 7.4, 50 mM
imidazole–HCl, 50 mM NaCl, 12.5 mM MgCl2, 1 mM
EGTA, 1 mM dithiothreitol, 5 AM ATP, 1 ACi of [g-32P]
ATP). Fifty micrograms Ag of protein/assay (cytoplasmic
fraction, isolated nuclei, nuclear matrix) was used. Reaction
volume was 100 Al. After a 30-min incubation at 25 jC, the
reaction was stopped by the addition of chloroform/metha-
nol/1% perchloric acid (1:2:0.75, v/v) and then vortexed.
After addition of 10 Ag unlabeled PA and 1% perchloric
acid/chloroform (1:1, v/v), the mixture was briefly micro-
fuged. The organic phase was washed twice in 1%perchloric acid, dried under a stream of nitrogen, and
spotted on Silica Gel G-60 TLC plates, which were devel-
oped with chloroform/methanol/H2O/ammonia (45:35:8:2).
Spots of interest were scraped and the amount of [g-32P] PA
was measured in a liquid scintillation counter. DGK activity
was found to be linear to time (15–60 min) and protein
concentration (20–100 Ag) (data not shown).
2.8. Western blot analysis
Protein (80 Ag/lane) was separated on sodium dodecyl-
sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to nitrocellulose sheets using a semi-dry
blotting apparatus. Sheets were saturated in PBS containing
5% NGS and 4% BSA for 60 min at 37 jC (blocking
buffer), then incubated overnight at 4 jC in blocking buffer
containing primary antibodies. After four washes in PBS
containing 0.1% Tween-20, they were incubated for 30 min
at room temperature with peroxidase-conjugated anti-mouse
IgG, diluted 1:5,000 in PBS–Tween-20, and washed as
above. Immunoreactive bands were visualized by the ECL
method.
2.9. In situ immunofluorescence
Cultures of PC12 cells (control and NGF-treated), grow-
ing on coverslips coated with rat tail collagen, were washed
twice in cold PBS, pH 7.2, fixed with freshly prepared 4%
paraformaldehyde (30 min at room temperature) and per-
meabilized with 0.2% Triton X-100 in PBS (10 min).
Samples were reacted (overnight at 4 jC) with the mono-
clonal antibody to DGK-u diluted 1:10 in 2% BSA, 3%
NGS in PBS. The secondary antibody (1 hour at 37 jC) was
a Cy3-conjugated anti-mouse IgG, diluted 1:500 in 2%
BSA, 3% NGS in PBS. Finally, the coverslips were
mounted in glycerol containing 1,4-diazabicyclo [2.2.2]
octane to retard fading.
2.10. CLSM and image processing analysis
Samples were imaged by a LSM410 confocal laser
scanning microscope (CLSM) (Zeiss, Oberckochen, Ger-
many). This confocal system was coupled with a 1-mW
HeNe ion laser as light source, used to reveal Cy3 signal
with whith a 543-nm wavelength. Samples were observed
with a 100, 1.3 numerical aperture, PlanNeofluar objective
lens. The image processing was performed using the Image-
Space software (Molecular Dynamics, Sunnyvale, CA).3. Results
3.1. NGF increases DGK activity in PC12 cell subfractions
We first assayed in vitro DGK activity in cytoplasmic
fraction or isolated nuclei prepared from NGF-stimulated
Fig. 1. DGK activity is increased in response to NGF treatment of PC12
cells. (A) Time course analysis of DGK activity in cytoplasmic fraction and
(B) isolated nuclei. DGK activity was measured in 50 Ag of protein for 30
min. The mixed micelles contained OG (55 mM), DG (0.25 mM), and PS
(1 mM). Data are from a single experiment performed in duplicate and are
representative of at least three experiments. (C) A TLC autoradiograph
representative of the results reported in panel (B). DGK inhibitor R59949
(final concentration: 1 AM) was added to the reaction mixture 10 min
prior to adding the mixed micelles.
Fig. 2. NGF treatment does not increase the amount of nuclear DGK-u.
Western blot analysis for DGK-u, lamin B, and h-tubulin in isolated nuclei
prepared from PC12 cells stimulated for increasing periods of time with
NGF (100 ng/ml). Nuclear protein (80 Ag/lane) was separated on SDS-
PAGE and blotted to nitrocellulose sheets. Immunoreactive bands were
revealed by ECL. The blots are representative of three separate
experiments.
Fig. 3. NGF treatment does not change the intranuclear spatial distribution
of DGK-u. (A) Untreated cells; (B) cells treated with NGF for 10 min; (C)
cells treated with NGF for 30 min; (D) cells treated with NGF for 60 min.
PC12 cells growing on glass cover slips, were stimulated with 100 ng/ml
NGF for the indicated times. They were then fixed, permeabilized, and
fluorescently immunolabeled for DGK-u. A Cy3-conjugated secondary
antibody was employed. Samples were analyzed with a CLSM. Scale bar:
1 Am.
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DGK activity showed that the activity maximally increased
at 5 min after stimulation. However, by 20 min, the activity
has returned to basal levels. This DGK activity was insen-
sitive to the DGK inhibitor R59949 (Fig. 1A).
In isolated nuclei, in vitro DKG activity started to
increase 10 min after NGF stimulation, peaked at 30 min,
and has returned to basal levels by 60 min. Also nuclear
DGK activity was insensitive to R59949 (Fig. 1B and C).3.2. NGF treatment neither increases nuclear amount of
DGK-h nor affects its intranuclear spatial distribution
Since our previous results indicated that DGK-h is
mainly concentrated in the nuclear speckle domains of
PC12 cells [18], we investigated whether or not in response
to NGF there was a change either in the nuclear amount or
in the intranuclear distribution of DGK-h. Western blot
analysis demonstrated that the quantity of DGK-h present
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(Fig. 2). Immunocytochemical staining coupled with CLSM
analysis showed that in untreated, serum-starved cells DGK-
h was mainly located in 25–50 irregular, punctate domains,
corresponding to speckles, as expected (Fig. 3A). However,
the spatial distribution of DGK-h did not change in response
to NGF challenging (Fig. 3B–D).
3.3. Anti-DGK-h antibody blocks the NGF-stimulated
nuclear DGK activity in vitro
Previous results from another group have demonstrated
that the monoclonal antibody to DGK-u employed in this
study could be used to inhibit the in vitro activity of nuclear
DGK-u, because it binds to this DGK isozyme in its
catalytic domain [17]. Therefore, we decided to employ this
antibody to establish whether or not DGK-u was responsibleFig. 4. Anti-DGK-u antibody blocks NGF-elicited DGK activity in isolated
nuclei. Cells were stimulated with NGF (100 ng/ml) for the indicated
times. Subcellular fractions [(A) cytoplasmic fraction; (B) isolated nuclei]
were then prepared. To disrupt nuclei, they were resuspended in 5 mM
Tris–HCl, pH 8.0, 0.1 mM EDTA, 100 IU/ml RNase-free DNase I, plus
the protease and phosphatase inhibitor cocktail (see Materials and
methods). After swelling on ice for 10 min, disruption was achieved by
60 passages through a 25-gauge hypodermic needle [17]. Either
monoclonal antibody to DGK-u (50 ng/ml) or an unrelated isotype
matched mouse IgG (50 ng/ml) was added to the samples (50 Ag protein),
which were then incubated overnight at 4 jC with constant agitation. DGK
activity assay was performed with mixed micelles containing OG (55 mM),
DG (0.25 mM), and PS (1 mM). Results are the mean of three different
experimentsF S.D.
Fig. 5. PS stimulates nuclear DGK activity. PC12 cells were challenged
with NGF (100 ng/ml) for the indicated times. Subcellular fractions [(A)
cytoplasmic fraction; (B) isolated nuclei] were then prepared. DGK activity
assay was performed with mixed micelles containing OG (55 mM), DG
(0.25 mM), and PS (either 1 mM: 1.8 mol%; or 5 mM: 8.3 mol%). Results
are the mean of three different experimentsF S.D.for the increase of DGK activity measured in isolated nuclei
prepared from NGF-stimulated PC12 cells.
Either cytoplasmic fraction or disrupted isolated nuclei
from untreated or NGF-treated cells were incubated over-
night (4 jC) with constant agitation in the presence or
absence of the monoclonal antibody to DGK-u. As a
control, we employed an unrelated, isotype matched mouse
monoclonal antibody. As shown in Fig. 4A, neither the anti-
DGK-u antibody nor the unrelated isotype mouse monoclo-
nal antibody was capable of affecting DGK activity of the
cytoplasmic fraction of untreated or 5 min NGF-treated
cells. In contrast, when this type of experiment was per-
formed using isolated nuclei, it was evident that the anti-
DGK-u antibody dramatically inhibited nuclear DGK activ-
ity measured in response to NGF treatment (30 or 45 min),
whereas the control antibody did not. Also, in nuclei
prepared from untreated cells, the anti-DGK-u antibody
significantly affected basal DGK activity (Fig. 4B). Overall,
the anti-DGK-u antibody inhibited approximately 75% of
nuclear DGK activity at all the investigated times.
3.4. Nuclear DGK activity is stimulated by PS
Since DGK-u is known for be activated by PS in IIC9
cells [17], we decided to analyze whether or not this was
Table 1
EGF increases nuclear DGK activity
Time (min) Without antibody With anti-DGK-u
antibody
0 53.2F 7.3 18.8F 2.4
5 55.4F 8.1 19.4F 2.7
10 161.9F 18.0 128.4F 16.4
30 240.3F 27.7 207.7F 23.5
60 59.9F 8.4 20.1F 3.3
Serum-starved PC12 cells were stimulated with EGF (40 ng/ml) for the
indicated times. Nuclei were then isolated and assayed for DGK activity.
DGK activity assay was performed with mixed micelles containing OG (55
mM), DG (0.25 mM), and PS (1 mM). Monoclonal antibody to DGK-u (50
ng/ml) was added to samples of disrupted nuclei (50 Ag protein), which
were then incubated overnight at 4 jC with constant agitation. Results are
the mean of three different experimentsF S.D. and are expressed as pmol
PA produced/mg protein.
Fig. 6. NGF stimulation increases the amount of nuclear matrix-bound
DGK-u. PC12 cells were incubated with NGF (100 ng/ml). The nuclear
matrix was then prepared from isolated nuclei by DNase I digestion and
0.6 M (NH4)2SO4 extraction. (A) Western blot analysis for DGK-u and
lamin B. N, isolated nuclei; S, supernatant after (NH4)2SO4 extraction;
NM, nuclear matrix. Protein (80 Ag/lane) was separated on SDS-PAGE
and blotted to nitrocellulose sheets. Immunoreactive bands were revealed
by ECL. The blots are representative of three separate experiments. (B)
DGK activity assay. Nuclear matrix was disrupted as for nuclei, except
that RNase-free DNase I was not employed. Either monoclonal antibody
to DGK-u (50 ng/ml) or an unrelated isotype matched mouse IgG (50
ng/ml) was added to the samples (50 Ag protein), which were then
incubated overnight at 4 jC with constant agitation. DGK activity assay
was performed with mixed micelles containing OG (55 mM), DG (0.25
mM), and PS (1 mM). Results are the mean of three different
experimentsF S.D.
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both the basal and the NGF-evoked DGK activity measured
in cytoplasmic fraction was actually slightly inhibited by
PS. In contrast, in isolated nuclei PS had a marked stimu-
latory effect on DGK activity (Fig. 5B).
3.5. NGF treatment increases nuclear matrix-bound DGK-h
Our own previous results have shown that in exponen-
tially growing MDA-MB-453 cells, DGK-u is a component
of the nuclear matrix [18]. The nuclear matrix is viewed by
several investigators as the fundamental organizing princi-
ple of the nucleus where many functions take place, includ-
ing DNA replication and transcription, and protein
phosphorylation [26,27]. Several enzymes involved in lipid
metabolism have been found associated with the nuclear
matrix (reviewed in Refs. [8,28]), an indication that the
matrix may also be involved in intranuclear signal trans-
duction pathways.
We therefore investigated whether or not DGK-u protein
and activity were associated with the nuclear matrix pre-pared from PC12 cells. Western blot analysis indicated that
in untreated cells, most of nuclear DGK-u was extracted by
the high ionic strength buffer (0.6 M (NH4)2SO4) used to
remove chromatin (Fig. 6A). iIn contrast, most of DGK-u
was bound to the nuclear matrix prepared from cells
stimulated for 30 min with NGF. As a control, we ana-
lyzed the behaviour of another nuclear matrix protein, i.e.,
lamin B [29]. The blots revealed that all of this protein
was associated with the nuclear matrix independently from
the state of the cells (either untreated or NGF-stimulated)
(Fig. 6A).
As far as nuclear DGK activity was concerned, in nuclei
prepared from control cells, about 21% of the activity was
matrix-bound. This activity was inhibited by the monoclonal
antibody to DGK-u (Fig. 6B). However, when the nuclear
matrix was prepared from 30 min NGF-stimulated PC12
cells, the percentage of nuclear DGK activity recovered in
the matrix fraction rose to about 79%. The antibody to
DGK-u inhibited 70% of the matrix-associated DGK activ-
ity (Fig. 6B).
3.6. EGF increases a nuclear DGK activity insensitive to
anti-DGK-h antibody
While NGF triggers neuronal differentiation of PC12
cells, EGF elicits a proliferative response (e. g., Ref. [30]).
Therefore, we investigated whether or not also in response
to EGF treatment, there was an increase in DKG activity. As
shown in Table 1, we detected an up-regulation of nuclear
DGK activity in response to EGF on a time scale similar to
that observed with NGF. Also, the amplitude of the activity
increase was the same. However, while at 0 min, 5 min, and
60 min approximately 75% of nuclear DGK activity was
inhibited by the blocking anti-DGK-u monoclonal anti-
body,, the EGF-elicited DGK activity was insensitive to it.
In fact, at 10 min of stimulation, only about 20% of the
activity was inhibited, while at 30 min inhibition was only
14%.
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Recent studies have indicated that DGK isoforms are
important components of the nuclear lipid metabolism (e.g.,
Refs. [15–18,24,31]).
In this report, we show that in response to NGF treatment
of serum-starved PC12 cells, there was an increase in DGK
activity both in the cytoplasmic and in the nuclear fraction.
However, activation of DGK in the cytoplasmic fraction
differed in many respects from that of nuclear DGK.
Cytoplasmic DGK activity peaked much earlier (5 min)
than nuclear activity (30 min), and was not inhibited by a
monoclonal antibody, which has been previously demon-
strated to selectively down–regulate DGK-u [17]. In con-
trast, this antibody dramatically inhibited both basal and
NGF-elicited nuclear DGK activity.
This finding strongly suggested that nuclear DGK-u is
a down-stream target of NGF-evoked signaling pathways.
Moreover, while cytoplasmic DGK activity was inhibited
by PS, nuclear DGK activity was stimulated by it. As far
as the effect of PS on DGK isozymes is concerned,
available data indicate that DGK-y and DGK-e isoforms
are inhibited by PS [32,33], whereas the DGK-u, -~ , and
-a isoforms are stimulated by this anionic phospholipid
[17,33,34].
Regarding the sensitivity of cytoplasmic and nuclear
DGK activity to the well-established DGK pharmacological
inhibitor R59949, both activities were markedly inhibited
when this chemical was included in the in vitro kinase assay.
R59949 is a selective and powerful inhibitor of DGK-a,
while other tested isoforms are either not or poorly inhibited
[35,36].
Taken together, these findings suggest that NGF acti-
vates nuclear DGK-u, whereas the cytoplasmic DGK
isoform, whose activity is also up-regulated by NGF,
remains to be identified, even though it could not be
DGK-a.
Recently, it has been shown that nuclear DGK-u is
activated in response to a-thrombin stimulation of IIC9
cells [17]. Overall, our results are in agreement with such
reports, even though there are some differences, which
most likely depends on the cell type being investigated. In
IIC9 cell nuclei, there is a basal DGK activity that is
completely insensitive to anti-DGK-u. In contrast, in PC12
cells basal nuclear DGK activity is also sensitive to the
antibody inhibition. Moreover, in a-thrombin-stimulated
IIC9 cells, there was a translocation of DGK-u from
cytoplasm to the nucleus, so that the intranuclear amount
of DGK-u increased upon a-thrombin incubation. This
nuclear migration was at least partially responsible for
the increased nuclear DGK-u activity [17]. At variance,
using both Western blot and immunofluorescence staining,
we have demonstrated that there are no changes in the
intranuclear amount of DGK-u in NGF-treated PC12 cells.
Also, the spatial distribution of DGK-u within the nucleus
was not affected by the cytokine. Indeed, in serum-starvedor NGF-exposed cells, DGK-u was concentrated in discrete
domains which correspond to speckles, as reported previ-
ously [18].
However, in response to NGF, there was a marked
increase in both the quantity and the enzymatic activity of
DGK-u, which remained associated with the nuclear matrix.
DGK-a has also been demonstrated to become associated
with the nuclear matrix of rat thymocytes and peripheral T-
lymphocytes in response to either concanavalin A or anti-T-
cell receptor antibody [37].
Association with the matrix may be responsible for the
increase in the activity of nuclear DGK-u measured after
NGF stimulation. Other enzymes, such as DNA primase
and polymerase-a, have been reported to become more
active upon binding to the nuclear matrix [38]. Among
the molecular mechanisms, which may control DGK
activity, there is phosphorylation/dephosphorylation. Both
DGK-a and –DGK-~ can be phosphorylated by PKC-a.
DGK-~ is negatively regulated by this phosphorylation
[39], while the effect on DGK-a is still unclear [40].
Furthermore, DGK-a, when activated, is phosphorylated
on tyrosine residue [36]. As to DGK-u, it can be
phosphorylated in vitro by PKC isoforms, but also in this
case, the outcome on enzymatic activity is yet to be
established [41]. In this connection, it is worth emphasiz-
ing that the nuclear matrix is a site for protein phosphor-
ylation [42] and that nuclear speckles contain protein
kinases and phosphatases [43].
Activation of nuclear DGK-u seems to be peculiar to
NGF, because EGF up-regulated a nuclear DGK activity,
which was not inhibited by the anti-DGK-u antibody. The
EGF-evoked nuclear DGK activity might correspond to the
DGK-~ isozyme, which has been observed to be a target of
EGF signaling in other cell types [16].
The function of intranuclear DGK isozymes has gener-
ally been related to attenuating DG-dependent signaling
events, such as attraction and activation of PKC isoforms
[15,17,24]. Consistently, in NGF-treated PC12 cells, there is
a nuclear migration of several DG-dependent PKC iso-
zymes, including PKC-a and PKC-hII [44,45].
However, it might be that nuclear DGK-u fulfills other
roles. Indeed, in nuclear speckles, it associates with phos-
phatidylinositol-4-phosphate 5-kinase [18], whose activity
can be stimulated by PA [46]. Considering that NGF
stimulates nuclear inositide metabolism by promoting phos-
phatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) synthesis
from PI(4,5)P2 [21,47], it might be that the enhanced
activity of DGK-u would produce PA necessary for stimu-
lating phosphatidylinositol-4-phosphate 5-kinase, which, in
turn, would synthesize additional PI(4,5)P2. It should be
emphasized here that PI(4,5)P2 also localizes to nuclear
speckles [18,48].
PA produced by DGK-u might also be involved in
regulating nuclear matrix structure and/or function, because
actin seems to be a critical component of the nuclear
skeleton [49]. In this connection, it seems interesting that
G. Tabellini et al. / Cellular Signalling 16 (2004) 1263–12711270the spatial distribution of small nuclear ribonucleoproteins
and intranuclear actin changed as early as 4 hour after
exposure of PC12 cells to NGF [50] and that these
changes might be related to the up-regulation of gene
expression [51]. However, PI(4,5)P2 by itself might also
influence actin and, by as a consequence, nuclear structure
and organization. In fact, a relationship between the
chromatin remodelling SWI/SNF-related complex BAF
and PI(4,5)P2 signaling has recently begun to emerge
recently. PI(4,5)P2 enhances the binding of the BAF
complex to the nuclear matrix [52]; PI(4,5)P2 binds BAF
at one molecule per complex, which, in turn, increases
actin polymerization in a PI(4,5)P2-sensitive manner, sug-
gesting that PI(4,5)P2 can induce the uncapping of actin,
leading to nucleation or filament assembly [53,54]. There-
fore, multiple functions may be envisaged for nuclear
DGK-u and its product PA.
Further investigations should shed more light on the
multiple emerging roles played by lipids and lipid second
messengers generated within the nucleus, as well as on the
mechanisms which regulate the enzymes involved in the
synthesis of these highly bioactive molecules.Acknowledgements
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Giraudo, W.J. van Blitterswijk, F. Busssolino, P.M. Comoglio, A.
Graziani, EMBO J. 19 (2000) 4614–4622.
[37] I. Wada, M. Kai, I. Shin-chi, F. Sakane, H. Kanoh, FEBS Lett. 393
(1996) 48–52.
[38] R.A. Tubo, R. Berezney, J. Biol. Chem. 262 (1987) 1148–1154.
[39] B. Luo, S.M. Prescott, M.K. Topham, J. Biol. Chem. 278 (2003)
39542–39547.
[40] D. Schaap, J. van der Wal, W.J. van Blitterswijk, R.L. van der Bend,
H.L. Ploegh, Biochem. J. 289 (1993) 875–881.
[41] W.J. van Blitterswijk, B. Houssa, Cell. Signal. 12 (2000) 595–605.
[42] K. Ahmed, Crit. Rev. Eukaryot. Gene Expr. 9 (1999) 329–336.
[43] A.I. Lamond, D.L. Spector, Nat. Rev. Mol. Cell Biol. 4 (2003)
605–612.
[44] P. Borgatti, M. Mazzoni, C. Carini, L.M. Neri, M. Marchisio, L.
Bertolaso, M. Previati, G. Zauli, S. Capitani, Exp. Cell Res. 224
(1996) 72–78.
[45] M.W. Wooten, G. Zhou, M.C. Wooten, M.L. Seibenhener, J. Neuro-
sci. Res. 49 (1997) 393–403.
[46] D.R. Jones, M.A. Sanjuan, I. Merida, FEBS Lett. 476 (2000)
160–165.
[47] K. Tanaka, K. Horiguki, T. Yoshida, M. Takeda, H. Fujisawa, M.
Umeda, S. Kato, S. Ihara, S. Nagata, Y. Fukui, J. Biol. Chem. 274
(1999) 3919–3922.
G. Tabellini et al. / Cellular Signalling 16 (2004) 1263–1271 1271[48] S.L. Osborne, C.L. Thomas, S. Gschmeissner, G. Schiavo, J. Cell. Sci.
114 (2001) 2501–2511.
[49] T. Pederson, Mol. Biol. Cell 11 (2000) 799–805.
[50] D.J. Sahlas, K. Milankov, P.C. Park, U. De Boni, J. Cell. Sci. 105
(1993) 347–357.
[51] P.C. Park, U. De Boni, Proc. Natl. Acad. Sci. U. S. A. 93 (1996)
11646–11651.[52] K. Zhao, W. Wang, O.J. Rando, Y. Xue, K. Swiderek, A. Kuo, G.R.
Crabtree, Cell 95 (1998) 625–636.
[53] I.A. Olave, S.L. Reck-Peterson, G.R. Crabtree, Annu. Rev. Biochem.
71 (2002) 755–781.
[54] O.J. Rando, K. Zhao, P. Janmey, G.R. Crabtree, Proc. Natl. Acad. Sci.
U. S. A. 99 (2002) 2824–2849.
